Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4, representing a platform software upgrade. No study content, terminology, or essential page functionality appears to be altered by this change.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page revision label was updated from Revision: v3.6.0 to Revision: v3.6.3, indicating a minor platform/content-management update.SummaryDifference0.0%

- Check41 days agoChange DetectedThe study record now shows that recruitment is no longer open to participants, indicating that enrollment is closed. New reader guidance sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the recruitment locations were updated to reflect Sariyer, Turkey, with a prior location removed, signaling changes to how participants can locate sites.SummaryDifference0.2%

- Check48 days agoChange DetectedThe revision tag in the page footer was updated from v3.5.4 to v3.5.5. This signals a minor behind-the-scenes update to the site.SummaryDifference0.0%

- Check55 days agoChange DetectedLocation data for a site in Ukraine was updated to use the official Kharkiv Oblast designation. The address line now reads Kharkiv, Kharkiv Oblast, Ukraine, 61070, replacing the previous Kharkivs’ka Oblast’ variant.SummaryDifference0.0%

- Check62 days agoChange DetectedA new publication reference has been added under Publications, citing a 2026 J Clin Oncol article about selpercatinib and postprogression therapies. This update enriches the study record with additional related literature tied to the trial.SummaryDifference0.0%

Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.